Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics

Abstract

Since the turn of the century, cancer therapy has undergone a transformation in terms of new treatment modalities and renewed optimism in achieving long-lived tumour control and even cure. This is, in large part, thanks to the widespread incorporation of monoclonal antibodies (mAbs) into standard treatment regimens. These new therapies have, across many settings, significantly contributed to improved clinical responses, patient quality of life and survival. Moreover, the flexibility of the antibody platform has led to the development of a wide range of innovative and combinatorial therapies that continue to augment the clinician's armoury. Despite these successes, there is a growing awareness that in many cases mAb therapy remains suboptimal, primarily due to inherent limitations imposed by the immune system's own homeostatic controls and the immunosuppressive tumour microenvironment. Here, we discuss the principal barriers that act to constrain the tumour-killing activity of antibody-based therapeutics, particularly those involving antibody glycans, using illustrative examples from both pre-clinical and market approved mAbs. We also discuss strategies that have been, or are in development to overcome these obstacles. Finally, we outline how the growing understanding of the biological terrain in which mAbs function is shaping innovation and regulation in cancer therapeutics.

More information

Identifiers

ORCID for Stephen Beers: orcid.org/0000-0002-3765-3342

ORCID for Mark Cragg: orcid.org/0000-0003-2077-089X

ORCID for Max Crispin: orcid.org/0000-0002-1072-2694

Catalogue record

Export record

Altmetrics